Condition: Advanced Solid Tumor · Advanced Lymphoma · Sponsor: CStone Pharmaceuticals
This is a first-in-human (FIH) study to evaluate the safety and preliminary efficacy of experimental drug CS5001 used as a single agent and in combination with systemic therapies in patients with advanced hematological and solid tumors.
This description comes directly from the study's public registry record.
Crystal Wang · 021-60332435 · wangjingru@cstonepharma.com
Always discuss trial participation with your own doctor first.
| North Shore Hematology Oncology Associates | East Setauket, New York, United States | Recruiting |
| Columbia U. - Herbert Irving Comprehensive Cancer Center | New York, New York, United States | Recruiting |
| BUMC - Mary Crowley Cancer Research Centers (MCCRC) | Dallas, Texas, United States | Recruiting |
| Scientia Clinical Research Limited | Randwick, New South Wales, Australia | Recruiting |
| Ashford Cancer Centre Research | Adelaide, South Australia, Australia | Terminated |
| Central Adelaide Local Health Network Incorporated | Adelaide, South Australia, Australia | Recruiting |
| Royal Adelaide Hospital (RAH) | Adelaide, South Australia, Australia | Recruiting |
| Epworth Freemasons Medical Centre | East Melbourne, Victoria, Australia | Recruiting |
| Epworth Foundation trading as Epworth HealthCare | Melbourne, Victoria, Australia | Not Yet Recruiting |
| Anhui Provincial Cancer Hospital | Hefei, Anhui, China | Not Yet Recruiting |
| Anhui Provincial Hospital, | Hefei, Anhui, China | Not Yet Recruiting |
| Beijing Cancer Hospital | Beijing, Beijing Municipality, China | Recruiting |
+ 26 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05279300